|
Apr 24
|
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
|
|
Apr 24
|
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
|
|
Apr 23
|
Why vaccine makers aren't worried about Trump administration cuts
|
|
Apr 23
|
Update: Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation
|
|
Apr 23
|
European Equities Surge Higher in Wednesday Trading; EC Fines Meta, Apple for DMA Violations
|
|
Apr 23
|
Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation
|
|
Apr 23
|
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi
|
|
Apr 23
|
Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement
|
|
Apr 23
|
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs
|
|
Apr 22
|
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
|
|
Apr 21
|
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
|
|
Apr 21
|
Sanofi and Regeneron’s dupilumab approved by FDA for urticaria
|
|
Apr 19
|
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
|
|
Apr 18
|
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
|
|
Apr 18
|
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
|
|
Apr 18
|
Stocks to watch this week: Tesla, Alphabet, Intel, Boeing and Unilever
|
|
Apr 17
|
Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
|
|
Apr 17
|
Sanofi licenses immune disease drugs from startup Earendil
|
|
Apr 16
|
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
|
|
Apr 15
|
Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement
|